Abstract
There is considerable interest in the therapeutic utility of inhibiting cellular trafficking in a variety of inflammatory diseases. Approaches including inhibition of adhesion molecule function and in particular of chemokine effector function have met with high levels of success in many models of disease but have been of less value in application to clinical disease states. Although this may in part be explained by pharmacokinetic and pharmacodynamic issues surrounding therapeutic agents tried thus far, it is also likely that functional redundancy in the chemokine network may pose significant problems for achieving potent inflammation suppression. The atypical chemokine receptors comprise a novel group of receptors capable of binding to several chemokine activities and to inhibiting their function. This review will describe the basic biology of such receptors and speculate on their potential as therapeutic agents moving forward.
Keywords: Chemokine, cytokine, inflammation, autoimmunity, pathogenesis, psoriasis
Current Molecular Medicine
Title: Atypical Chemokine Receptors in Inflammatory Disease
Volume: 9 Issue: 1
Author(s): Manish Patel, Iain B. McInnes and Gerard Graham
Affiliation:
Keywords: Chemokine, cytokine, inflammation, autoimmunity, pathogenesis, psoriasis
Abstract: There is considerable interest in the therapeutic utility of inhibiting cellular trafficking in a variety of inflammatory diseases. Approaches including inhibition of adhesion molecule function and in particular of chemokine effector function have met with high levels of success in many models of disease but have been of less value in application to clinical disease states. Although this may in part be explained by pharmacokinetic and pharmacodynamic issues surrounding therapeutic agents tried thus far, it is also likely that functional redundancy in the chemokine network may pose significant problems for achieving potent inflammation suppression. The atypical chemokine receptors comprise a novel group of receptors capable of binding to several chemokine activities and to inhibiting their function. This review will describe the basic biology of such receptors and speculate on their potential as therapeutic agents moving forward.
Export Options
About this article
Cite this article as:
Patel Manish, McInnes B. Iain and Graham Gerard, Atypical Chemokine Receptors in Inflammatory Disease, Current Molecular Medicine 2009; 9 (1) . https://dx.doi.org/10.2174/156652409787314480
DOI https://dx.doi.org/10.2174/156652409787314480 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Association of Apolipoprotein E (ApoE) Polymorphism with Alzheimer's Disease in Chinese Population
Current Alzheimer Research Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design Bilirubin Chemistry and Metabolism; Harmful and Protective Aspects
Current Pharmaceutical Design Sphingolipids in Inflammation: Roles and Implications
Current Molecular Medicine Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer
Reviews on Recent Clinical Trials Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry TNF Receptor: Fc Fusion Protein Downregulates RANKL/OPG Ratio by Inhibiting CXCL16/CXCR6 in Active Ankylosing Spondylitis
Current Pharmaceutical Biotechnology Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Epigenetic Regulation of Myocardial Homeostasis, Self-Regeneration and Senescence
Current Drug Targets Role of Subclinical Iatrogenic Hyperthyroidism in the Setting of Heart Disease and Arrhythmic Burden
Endocrine, Metabolic & Immune Disorders - Drug Targets Erythropoietin and Oxidative Stress
Current Neurovascular Research Pharmacotherapy in Neonatal and Pediatric Extracorporeal Membrane Oxygenation (ECMO)
Current Drug Metabolism Cigarette Smoking and Angiogenesis: What is the Role of Endothelial Progenitor Cells?
Current Angiogenesis (Discontinued) Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy Human Amnion–Derived Cells as a Reliable Source of Stem Cells
Current Molecular Medicine Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry